Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Chile Exports

9 Sep 2008 07:00

RNS Number : 9848C
Beximco Pharmaceuticals Ltd
09 September 2008
 



BEXIMCO PHARMACEUTICALS LTD.

9 September 2008

Beximco Pharma commences exports to Chile

Beximco Pharmaceuticals Ltd. ("BPL" or the "Company"), the leading pharmaceutical manufacturer and the largest exporter of pharmaceutical products from Bangladesh, today announces that it has commenced exports to Chile, after receiving marketing authorization for a number of products from "Instituto de Salud Publica de Chile" (Drug Regulatory authority in Chile). With this, BPL has become the first Bangladeshi pharmaceutical company to obtain product registration in any Latin American country.

Chile is the sixth largest pharmaceutical market in Latin AmericaIn 2007, the Chilean pharmaceutical market was valued at US$1.5 billion. 

Beximco Pharma CEO Mr. Nazmul Hassan said:

"Our entry into Latin America marks another milestone in the Company's plan to become a global pharmaceutical company. With a market size of around US$40 billion and with a high growth rate, Latin America is considered as one of the biggest pharmaceutical markets and it is strategically important for us in our global expansion programBeing successful in registering our products in Chile will mark our presence in the regionWe continue to seek similar opportunities and are actively working in other Latin American countries." 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan, CEO

Tel: +880 2 861 9151, ext.2080

 

Libertas Capital

Aamir Quraishi / Andrew Hardy

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

David Yates / Susan Quigley

Tel: +44 (0)20 7269 7169

 

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in DhakaBangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri LankaNepalBhutanVietnamCambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUWANRWSRKRAR
Date   Source Headline
5th Mar 20269:13 amRNSUpdate on Writ Petitions
28th Jan 20262:01 pmRNSOrder re Extension to Publish Financial Results
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
13th Nov 20254:00 pmRNSRequest of Extension to Publish Q1 Results
4th Nov 20257:00 amRNSChange of Name to Beximco Pharmaceuticals PLC.
27th Oct 20253:53 pmRNSRequest of Extension to Publish Financial Results
24th Oct 20257:00 amRNS-RAffordable treatment option for cystic fibrosis
15th Sep 20251:17 pmRNSFurther update on BSEC Order
21st May 20253:18 pmRNSUpdate on BSEC Order
28th Apr 20257:00 amRNSRequest of Extension to Publish Q3 Results
21st Mar 20253:51 pmRNSResponse to media reports and update on BSEC order
6th Mar 20257:00 amRNSUpdate on BSEC order
30th Jan 20252:59 pmRNSPayment of Cash Dividend
29th Jan 20257:01 amRNSBoard Changes
29th Jan 20257:00 amRNSHalf Year Results 2024-25
14th Jan 202511:24 amRNSBoard of Directors
30th Dec 20247:00 amRNSAnnual General Meeting Statement
19th Nov 20247:00 amRNSAGM Notification
14th Nov 20247:00 amRNSFinancial Results for the First Quarter
12th Nov 202410:00 amRNSRestoration - Beximco Pharmaceuticals Limited
12th Nov 202410:00 amRNSUpdate on Interim Order Supreme Court decision
11th Nov 202411:01 amRNSFurther re the Temporary Suspension of Trading
11th Nov 20247:30 amRNSSuspension - Beximco Pharmaceuticals Limited
7th Nov 20247:00 amRNSResults for the year ended 30 June 2024
29th Oct 20247:00 amRNSNotification of Preliminary Results and AGM
28th Oct 20242:35 pmRNSUpdate on Writ Petition and Interim Order
2nd Oct 20247:00 amRNSUpdate on Writ Petition and Interim Order
30th Sep 20247:06 amRNSClarification on Writ Petition
6th Sep 20242:17 pmRNSUpdate regarding Vice-Chairman, Salman Rahman
3rd Sep 20241:45 pmRNSCorrection and Clarification of Press Commentary
15th Aug 20247:00 amRNSStatement regarding Vice-Chairman, Salman Rahman
13th Aug 20247:00 amRNSStatement on political and business situation
30th Apr 20247:00 amRNSQ3 Financial Results
4th Mar 20247:00 amRNSAppointment of Managing Director
30th Jan 20247:00 amRNSHalf Year Results 2023-24
25th Jan 20249:53 amRNSPayment of Cash Dividend
11th Jan 202411:44 amRNSBoard Change
28th Dec 20239:40 amRNSAGM Statement
6th Nov 202312:17 pmRNSNotice of AGM
6th Nov 20237:00 amRNSFinancial Results for the First Quarter
1st Nov 20237:00 amRNSResults for the year ended 30 June 2023
20th Oct 20237:00 amRNSNotification of Preliminary Results and AGM
11th Sep 202310:17 amRNSClarification on Press Report
31st Aug 20233:51 pmRNSRe-appointment of Independent Director
2nd May 20237:00 amRNSQ3 Financial Results
11th Apr 20233:59 pmRNSHoldings in Company
31st Mar 202311:03 amRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.